Date published: 2026-2-14

1-800-457-3801

SCBT Portrait Logo
Seach Input

hnRNP E3 Inhibitors

Heterogeneous nuclear ribonucleoprotein E3 (hnRNP E3) is a multifunctional RNA-binding protein that plays crucial roles in various aspects of RNA metabolism, including pre-mRNA splicing, mRNA stability, translation, and transport. As a member of the hnRNP family, hnRNP E3 contributes to the regulation of gene expression by binding to specific RNA sequences and modulating their processing and function. Its diverse functions are facilitated by its ability to interact with other proteins and RNA molecules, forming dynamic ribonucleoprotein complexes that participate in intricate regulatory networks within the cell. Notably, hnRNP E3 has been implicated in the regulation of alternative splicing, where it can act as both a splicing enhancer and suppressor depending on the context, thereby influencing the diversity of protein isoforms produced from a single gene.

Inhibition of hnRNP E3 activity can be achieved through various mechanisms that disrupt its binding to RNA or its interactions with other proteins, thereby interfering with its regulatory functions. One strategy involves the use of small molecules or peptides that specifically target the RNA-binding domains of hnRNP E3, preventing its association with target RNA molecules. Alternatively, inhibition may be achieved through the modulation of post-translational modifications that regulate hnRNP E3's activity or stability. For example, phosphorylation and acetylation have been shown to affect hnRNP E3's subcellular localization and its ability to interact with RNA and other proteins. Additionally, strategies aimed at disrupting protein-protein interactions involving hnRNP E3 can also effectively inhibit its function. By targeting specific binding partners or structural motifs critical for complex formation, it is possible to attenuate hnRNP E3-mediated regulatory processes. Overall, inhibition of hnRNP E3 offers a promising approach for studying its biological functions and modulating gene expression in various physiological and pathological contexts.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

2-Deoxy-D-glucose

154-17-6sc-202010
sc-202010A
1 g
5 g
$70.00
$215.00
26
(2)

A glucose analog that inhibits glycolysis, potentially reducing HKDC1 activity by competing with glucose for binding and phosphorylation.

Metformin

657-24-9sc-507370
10 mg
$79.00
2
(0)

An anti-diabetic drug that alters hepatic glucose production and improves insulin sensitivity, possibly impacting HKDC1 activity indirectly.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

An mTOR inhibitor, affects cellular energy metabolism, potentially influencing HKDC1 activity through metabolic changes.

Wiskostatin

253449-04-6sc-204399
sc-204399A
sc-204399B
sc-204399C
1 mg
5 mg
25 mg
50 mg
$49.00
$124.00
$441.00
$828.00
4
(1)

Glucose transporter 1 (GLUT1) inhibitor, can reduce glucose uptake and potentially influence HKDC1 activity.

Acarbose

56180-94-0sc-203492
sc-203492A
1 g
5 g
$226.00
$605.00
1
(1)

An alpha-glucosidase inhibitor, affects carbohydrate digestion and absorption, potentially impacting HKDC1 activity.

Phloretin

60-82-2sc-3548
sc-3548A
200 mg
1 g
$64.00
$255.00
13
(1)

A natural compound inhibiting GLUT transporters, could indirectly reduce HKDC1 activity by decreasing glucose availability.

Lonidamine

50264-69-2sc-203115
sc-203115A
5 mg
25 mg
$105.00
$364.00
7
(1)

Inhibits hexokinase, potentially affecting HKDC1 activity indirectly by reducing overall hexokinase activity in cells.

Sodium dichloroacetate

2156-56-1sc-203275
sc-203275A
10 g
50 g
$55.00
$209.00
6
(1)

Inhibits pyruvate dehydrogenase kinase, affecting glucose metabolism and potentially HKDC1 activity.

Quercetin

117-39-5sc-206089
sc-206089A
sc-206089E
sc-206089C
sc-206089D
sc-206089B
100 mg
500 mg
100 g
250 g
1 kg
25 g
$11.00
$17.00
$110.00
$250.00
$936.00
$50.00
33
(2)

A flavonoid that influences various signaling pathways, including glucose metabolism, potentially affecting HKDC1.

Rosiglitazone

122320-73-4sc-202795
sc-202795A
sc-202795C
sc-202795D
sc-202795B
25 mg
100 mg
500 mg
1 g
5 g
$120.00
$326.00
$634.00
$947.00
$1259.00
38
(1)

A PPAR-gamma agonist, alters insulin sensitivity and glucose uptake, which could indirectly affect HKDC1 activity.